Me-Too Drugs and Me-Too People
Author:
- 1 December 2013
- journal article
- viewpoint
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 149 (12) , 1375-1376
Abstract
Like hypotheses, concepts are important to our understanding and point the direction for actions and tests. The concept of me-too drugs is simple and powerful and misleadingly deemphasizes the value of these drugs for patients and physicians. The term me-too drug has been used in several ways, by some even to mean a generic drug.1 However, the term is historically and most accurately used to describe a drug with a mechanism of action similar to a drug already on the market. Although chemically distinct, the me-too drug will usually have a chemical structure that is similar to the first-to-market drug, which is viewed as having established the therapeutic category. These category-creating drugs are also called innovator or breakthrough drugs. Corticosteroids, retinoids, and antihistamines are examples familiar to dermatologists.Keywords
This publication has 3 references indexed in Scilit:
- Stress can affect drug pharmacokinetics via serum/tissues protein binding and blood flow rate alterationsEuropean Journal of Drug Metabolism and Pharmacokinetics, 2011
- Geographical genomics of human leukocyte gene expression variation in southern MoroccoNature Genetics, 2009
- Nelfinavir Pharmacokinetics in Stable Human Immunodeficiency Virus-Positive Children: Pediatric AIDS Clinical Trials Group Protocol 377Pediatrics, 2003